Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]

Recognizing and Investigating the Prodromal Phase in MS and NMOSD: Dalia Rotstein, MD, MPH

Articles

The 80 mg QD dosage, which showed the greatest efficacy in lesion reduction (92.3% at 24 weeks), will be used in phase 3 progressive MS studies.

BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on dementia.

NeurologyLive® Brain Games: March 2, 2025

At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]

Investigating Immune Cell Signatures in Multiple Sclerosis Progression: Stephanie Zandee, PhD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Amber Freed, founder of SLC6A1 Connect, shared her personal journey and advocacy efforts to raise awareness for SLC6A1, a rare genetic epilepsy, in honor of Rare Disease Day.

Rare Disease Day 2025: Transforming Challenges Into Action for SLC6A1

Staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]

Ways to Align Patient Characteristics of Progressive Multiple Sclerosis Trials With Clinical Reality: Robert J. Fox, MD

Mary Schroth, MD, FAAP, FCCP, chief medical officer at Cure SMA, shed insight on the advances and promise for treating spinal muscular atrophy, in the context of Rare Disease Day.

Rare Disease Stories of Success: Newfound Hope for Spinal Muscular Atrophy

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed key insights into patient characteristics and lesion differences of the CALLIPER Trial in retrospect to other studies. [WATCH TIME: 4 minutes]

Insights on Baseline Characteristics From Major Clinical Trials in Progressive Multiple Sclerosis: Robert J. Fox, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

ISC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

a headache neurologist and vice chair of BrainPac and the Headache & Facial Pain Section of AAN. It features articles on bringing lecanemab to neurology community clinics, a checklist for college age-people living with migraine, and a provider's cheat sheet to understanding sleep care; and a 

 examination of histone deacetylase inhibitors like givinostat in Duchenne muscular dystrophy.

Fall 2024

, the medical director of the MS Center at Holy Name Medical Center in Teaneck, New Jersey. It features articles on emerging MRI, OCT, CSF, and blood biomarkers for multiple sclerosis (MS); perspectives on self-managing MS via general consensus, insights from the MS-Selfie project, and a technology-based model; and a 

 examination of amifampridine in the treatment of Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.

Summer 2024

Spring 2024

November 2023

October 2023

August 2023

June 2023

April 2023

February 2023

December 2022

November 2022

October 2022

August 2022

June 2022

April 2022

February 2022

December 2021

November 2021

October 2021

August 2021

June 2021

 Cure Connections special issue, "The Multiple Sclerosis Patient Journey," includes a review of key topics that impact patients with multiple sclerosis, including diagnosis, psychological implications, and treatments.  

The Multiple Sclerosis Patient Journey

April 2021

February 2021

This downloadable PDF provides you with insight and best practices from a collective of experts in the management of multiple sclerosis on the diagnosis and treatment of the disease, with a focus on the latest first-line therapies, balancing quality of life, managing fatigue, and the pipeline of future agents.